Search

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

EHA-Balkan Hematology Day 2023

EHA is joining forces with the national societies from the Balkan countries and co-organizing with them the 4th edition of the EHA-Balkan Hematology Day.

Read more

EHA Kick-off Grants

The call for applications is closed. The EHA Kick-off Grant is a one-year grant intended to support basic and translational early career researchers in hematology.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2023 - report

October 26, 2023 – São Paulo, Brazil

Meeting chairs:

A Almeida - President EHA

JF Comenalli Marques Jr - President ABHH

C Chiattone - President HEMO 2023

This year, the HOPE LA meeting was held in collaboration with the Associação Brasileira de Hematologia Hemoterapia e…

Read more

Revision of the EU’s pharmaceutical legislation

Background on the reformIn April 2023, the European Commission (EC) published two proposals to revise the existing (and outdated) pharmaceutical legislation. This includes legislation on medicines for children and rare diseases.

Read more

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more